Evidence map›Paper›PMID 12024025›Full record

ArticleMolecular and cellular biology2002

Proteasomal inhibition enhances glucocorticoid receptor transactivation and alters its subnuclear trafficking.

Bonnie J Deroo, Claudia Rentsch, Sowmini Sampath, Janel Young, Donald B DeFranco, Trevor K Archer

Open access · greenAbstract read
In one paragraph

Article in Molecular and cellular biology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 159 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Glucocorticoid therapy and ocular hypertension.European journal of pharmacology · 2016
    Review
  14. Article
  15. Review
  16. Corticosteroids: Mechanisms of Action in Health and Disease.Rheumatic diseases clinics of North America · 2016
    Review
  17. Article
  18. Article
  19. Article
  20. Review

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Bonnie J DerooChromatin and Gene Expression Section, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina 27709, USA.
Claudia Rentsch
Sowmini Sampath
Janel Young
Donald B DeFranco
Trevor K Archer
University of Pittsburgh · USNational Institutes of Health · US

Funding

Development Of New Hormone Responsive Models From CancerZ01ES071007 · NIEHS · ENVIRONMENTAL HEALTH SCIENCES · PI ARCHER, TREVOR K · 1999 to 2002
–
6 · The paper itself

Abstract

The ubiquitin-proteasome pathway regulates the turnover of many transcription factors, including steroid hormone receptors such as the estrogen receptor and progesterone receptor. For these receptors, proteasome inhibition interferes with steroid-mediated transcription. We show here that proteasome inhibition with MG132 results in increased accumulation of the glucocorticoid receptor (GR), confirming that it is likewise a substrate for the ubiquitin-proteasome degradative pathway. Using the mouse mammary tumor virus (MMTV) promoter integrated into tissue culture cells, we found that proteasome inhibition synergistically increases GR-mediated transactivation. This increased activation was observed in a number of cell lines and on various MMTV templates, either as transiently transfected reporters or stably integrated into chromatin. These observations suggest that the increase in GR-mediated transcription due to proteasome inhibition may occur downstream of the initial chromatin remodeling step. In support of this concept, the increase in transcription did not correlate with an increase in chromatin remodeling, as measured by restriction enzyme hypersensitivity, or transcription factor loading, as exemplified by nuclear factor 1. To investigate the relationship between GR turnover, transcription, and subnuclear trafficking, we examined the effect of proteasome inhibition on the mobility of the GR within the nucleus and association of the GR with the nuclear matrix. Blocking GR turnover reduced the mobility of the GR within the nucleus, and this correlated with increased association of the receptor with the nuclear matrix. As a result of proteasome inhibition, GR mobility within the nucleus was reduced while its association with the nuclear matrix was increased. Thus, while altered nuclear mobility of steroid receptors may be a common feature of proteasome inhibition, GR is unique in its enhanced transactivation activity that results when proteasome function is compromised. Proteasomes may therefore impact steroid receptor action at multiple levels and exert distinct effects on individual receptor types.

Indexed as

Breast NeoplasmsCell NucleusChromatinCysteine EndopeptidasesCysteine Proteinase InhibitorsDNA-Binding ProteinsDNA HelicasesFemaleHistone AcetyltransferasesHumansLeupeptinsMammary Tumor Virus, MouseMultienzyme ComplexesNuclear ProteinsNuclear Receptor Coactivator 1Promoter Regions, Geneticbenzyloxycarbonylleucyl-leucyl-leucine aldehydeChromatinCysteine EndopeptidasesCysteine Proteinase InhibitorsDNA-Binding ProteinsDNA HelicasesHistone AcetyltransferasesLeupeptinsMultienzyme ComplexesNCOA1 protein, humanNcoa1 protein, mouseNuclear ProteinsNuclear Receptor Coactivator 1Proteasome Endopeptidase ComplexReceptors, GlucocorticoidRepressor ProteinsSIN3A transcription factorSin3 Histone Deacetylase and Corepressor ComplexSMARCA4 protein, humanSmarca4 protein, mouseSMARCC2 protein, humanTranscription Factors

Identifiers

PMID12024025
PMCPMC133869
OpenAlexW2078950703

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.